06/03/2025
The Board of Directors of Hypertension Canada is pleased to announce the appointment of Dr. Mohsen Agharazii to the position of Vice President, effective April 17, 2025.
Dr. Agharazii has served on the HC Board since 2023, and is a professor of medicine at Université Laval, a nephrologist, and the director of the Endocrinology-Nephrology research axis at the Chu de Québec Hospital in Quebec City. He has done his medical training at Université Laval, followed by research training in Paris at HEGP and Manhès Hospital under the supervision of Professors Stéphane Laurent, Pierre Boutouyrie and Gérard London.
Over the past decade he has developed his research program which focuses on the mechanisms of large artery remodeling in the context of CKD, both in humans and in animal models. His research has been supported by the Canadian Institute of Health Research, Kidney Foundation of Canada, and Heart and Stroke Foundation and the Canadian Foundation for Innovation. He has received research scholarships from Fonds de recherche du Québec – Santé and he has been awarded with the Université Laval-Amgen Research Chair in nephrology, and he is the author or co-author of more than 100 peer reviewed articles in the field of nephrology and hypertension.
